A koronavírus vakcinájának első emberen kipróbált tesztje: egyelőre minden rendben
Az angol cikk teljes fordítását E-mailben elküldöm a VIP előfizetőknek. VIP előfizető egy évre az lehet, aki 10.000 forint adománnyal hozzájárul a honlap fenntartásához.
First human test of a vaccine: So far, so good
We got an encouraging report on Monday about the first coronavirus vaccine to be tested in people, and not just in the lab. The manufacturer said the vaccine appeared to be safe and able to stimulate an immune response in a Phase 1 trial.
That doesn’t prove it works. It was a small trial — just eight people, all healthy volunteers between 18 and 55 — and the data hasn’t been shared publicly. Still, it would appear to be an important step in the right direction, one the world has been desperate to take.
A company called Moderna is collaborating on the vaccine with the agency led by Dr. Anthony Fauci, the National Institute of Allergy and Infectious Diseases, which has been leading the clinical trials (more are being conducted).
The company said the eight volunteers all produced at least as many virus-neutralizing antibodies as you would see in someone who recovered from Covid-19. That’s the point of a vaccine, to get the body to produce those antibodies without becoming sick. And when they were tested in the lab, Moderna said, the antibodies stopped the virus from replicating — another good sign.
It will take larger, longer studies to determine whether this vaccine can protect people from getting the virus in real-world conditions. It’s not even certain yet that antibodies can do that for this virus, or how long the protection might last.
Moderna’s technology, involving genetic material called mRNA, is relatively new and has yet to produce an approved vaccine for any disease. Even so, the positive signs for this one thrilled Wall Street.